CURN
CURATIS N AG
Stock SIX Swiss Exchange – Stock Market Prices, News & Analysis
Swiss company active in pharmaceutical research and development, with a strong focus on immunotherapies and innovative treatments for serious diseases.
CURATIS N AG
CURN
Swiss company active in pharmaceutical research and development, with a strong focus on immunotherapies and innovative treatments for serious diseases.
Price history of CURATIS N AG
Price history of CURATIS N AG
Performance & Momentum
Strategic Analysis
CURATIS N AG • 2026
CURATIS N AG is a Swiss biotechnology company specialized in the development of innovative immunotherapy treatments targeting serious diseases that are underserved or poorly treated. Its model is based on advanced clinical research to deliver differentiated pharmaceutical solutions in a sector with high technological barriers.
- Positioning in immunotherapy, a segment with strong medical and commercial potential.
- Expertise in clinical research enabling an innovative pipeline.
- Presence in a recognized Swiss pharmaceutical hub known for quality and scientific rigor.
- Historical performance has been volatile and marked by significant long-term declines.
- Lack of recent news flow, which may limit short-term visibility.
The stock’s recent momentum has been positive over the medium term, suggesting renewed investor interest in the sector or in the pipeline outlook. This trend calls for close monitoring of clinical developments to confirm a sustainable recovery.
Similar stocks to CURATIS N AG
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
